Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Brexucabtagene autoleucel is approved for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL) after two or more lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor
The pivotal ZUMA-2 trial, which involved 74 adults with Mantle Cell Lymphoma (MCL) whose cancer had come back after at least two previous treatments, including a Bruton's tyrosine kinase (BTK) inhibitor, showed that around 59% o…